Diagnostic Microbiology and Infectious Disease 1995: Vol 21-23 Index

14 Pages·1995·6.6 MB·English

DIAGN MICROBIOL INFECT DIS
1996;23:165-166
Author Index to Volumes 21-23
Aberer, E., 21:121 Cooper, B., 21:47 Hartstein, A.I., 22:309
Abreu, C., 22:125 Cooper, R.M., 21:61 Hayden, M.K., 22:349
Adolph, A.J., 22:361 Cormican, M.G., 21:51, 21:227, 22:43, 22:119, Hayden, R.T., 23:1
Aguiar Nogueira, J., 22:125 22:357, 23:157 Heelan, J.S., 22:321
Ahlquist, A., 22:163 Cota Koury, M., 22:343 Heyes, B., 21:69
Alam, A.N., 21:215 Craft, B., 22:155 Hogue, S.S., 21:215
Albert, M.J., 21:215, 22:337, 23:155 Craig, W.A., 22:89 Hollis, R.J., 21:9, 21:191, 23:99
Aldeen, W.E., 21:77 Cuadros, J.A., 21:115 Hsieh, W.-C., 21:81, 23:105, 23:147
Aldridge, K.E., 21:153, 22:35, 22:195 Cuenca, M., 22:339 Hu, B.-S., 22:285
Allen, $.D., 21:153, 21:175 Cynamon, M.T., 23:111 Hurley, J.C., 22:331
Anderson, S.C., 21:85, 21:95
Andrassy, K., 22:85 Dajani, A.S., 22:105 Jacobs, J.A., 22:267
Aprahamian, C., 22:183
Dalton, H.P., 21:61 Jamieson, F., 21:69
Ardanuy, C., 21:21
Damiani, A., 21:195 Jenkins, S.G., 23:53
Arroyo, V., 22:141 Davey, P., 22:225 Johnson, C.C., 21:169
Azad, A.K., 22:337
Dietz, H., 22:5 Johnson, D.M., 21:209, 23:123
The Aztreonam Study Group, 22:249
Doern, G.V., 22:13, 23:15, 23:119 Johnson, W., 21:69
Dressel, D.C., 23:1 Joho, K.L., 21:55
Baker, D.M., 21:61 Jonas, V., 22:297
Ballou, D., 21:15 Egleton, J.H., 22:301 Jones, R.N., 21:1, 21:51, 21:57, 21:85, 21:95,
Balows, A., 22:307 Emery, D.D., 23:85 21:105, 21:111, 21:153, 21:181, 21:209, 21:
Baltzan, R.B., 22:361 Ena, J., 21:115 227, 22:19, 22:43, 22:119, 22:243, 22:307, 22:
Barchiesi, F., 23:99 The Enterococcus Study Group, 21:85 315, 22:353, 23:10, 23:123, 23:157
Baron, E.J., 21:141, 23:23, 23:35, 23:75 Eriksson, L., 22:163 Jorgensen, J.H., 21:175
Barrett, M.S., 23:10 Eriksson, S., 22:163
Barry, A.L., 21:175 Erwin, M.E., 21:85, 21:95, 21:105, 22:119 Kakizoe, T., 23:129
Barton, A.L., 23:119 Escriba, J.M., 21:21 Kaplan, R.L., 21:223
Bell, J.M., 21:135 Kappel, J.E., 22:361
Benito, N., 22:339 Fan, K., 21:195 Kauffman, C.A., 21:27, 23:135
Bennion, D.W., 21:203 Fedorko, D.P., 23:85 Kawanishi, K., 23:77
Bergquist, S.O., 22:163
Kearns, G.L., 22:97
Ferraro, M.]., 22:297
Berk, S.L., 23:141 Flynn, J., 22:357 Keller, C., 22:159
Bernard, K., 21:101 Franklin, S.M., 23:85 Kendrew, J., 22:307
Beskid, G., 21:33 Freeman, C., 21:47 Khan, A.M., 22:337, 23:155
Bestrom, J.E., 22:275 Kibriya, A.K.M.G., 21:215
Friedman, H.D., 23:111
Bhattacharya, M.K., 22:337, 23:155
Fritzinger, D., 23:111 Klade, H., 21:121
Biedenbach, D.J., 21:1, 21:57, 22:315, 23:123 Klarlund, M., 21:219
Fuchs, P.C., 21:153, 21:175
Blondeau, J.M., 22:361 Fujita, J., 23:77 Kujath, P., 22:203
Bonaventura, M., 23:111
Funke, G., 22:293
Boschman, C.R., 23:1
Lamarche, D., 22:321
Boyle, C.A.J., 21:101
Gadea, I., 22:339 Lambert, J.R., 21:135
Bradley, S.F., 21:27
Lamy, Y., 23:111
Gannon, F., 22:357
Breier, F., 21:121
Lau, Y.-J., 22:285
Garcia, A., 21:21
Brown, G., 22:297
Lawrence, E., 22:307
Gatson, A.M., 22:325
Bruch, H.-P., 22:203
Lecour, H., 22:125
Burke, J.P., 22:167 Gelfand, M.S., 22:35, 22:155
Lee, C.K.K., 22:231
Gerlach, E.H., 21:153
Lee, J., 22:239
The German Cefotaxime Study Group, 22:
Caballero, O.L., 22:343 LeMonte, A.M., 22:309
203
Carlquist, J.F., 21:203
Letourneau, C., 22:321
Gilson, G.J., 21:65
Carlson, J.A., 22:239 Levison, M.E., 21:169
Glen, D.J., 22:231
Carroll, K., 21:77 Lin, Y.-H., 22:285
Carvajal, A., 21:21 Glennon, M., 22:357
Liu, P.Y.-F., 22:285
Carvalho, J., 22:343 Gomez-Herrus, P., 21:115 Liu, X., 21:129
Chamberlain, M.A., 22:239 Gonzalez-Palacios, R., 21:115 Lloyd, J.F., 22:167
Chang, S.-C., 21:81, 23:105, 23:115, 23:147 Grogan, J., 22:155 Lode, H., 22:1
Chapin, K., 23:35 Gustafson, D.R., 22:279 Lonnbro, N., 22:163
Chen, H.-C., 23:115 Gutierrez, C., 23:141 Lu, D.C.-T., 23:115
Chen, Y.-C., 23:105, 23:147 Luger, A., 21:121
Chetchotisakd, P., 22:309 Hadfield, T.L., 23:111 Luh, K.-T., 21:81, 23:105, 23:147
Clarridge, J.E., 21:15 Hale, D., 21:77
Classen, D.C., 22:167 Hall, G.S., 21:187 Mackenzie, A., 21:69
Congdon, D.D., 23:85 Harrington, G.D., 21:27 Marshall, S.A., 21:51, 21:153, 22:249, 22:353,
Conly, J.M., 21:101, 22:135 Hartskeerl, R.A., 22:343 23:123, 23:157
Author Index to Volumes 21-23
Martin, R., 21:21 Putnam, S.D., 23:10 Smith, T., 22:357
Martinez-Lacasa, J.T., 21:21 Pylypchuk, G.B., 22:361 Soeters, P.B., 22:267
Marx, C.E., 21:195 Soliman, H., 21:55
Matushek, M.G., 22:349 Quintiliani, R., 21:47, 22:49, 22:189 Soriano, F., 22:339
May, P., 21:169 Spiegel, J.E., 23:135
Mazens-Sullivan, M., 21:47 Staneck, J.L., 23:61
Raddatz, J.K., 22:77
Mclver, C.J., 22:261 Steaffens, J.W., 22:253
Ramirez, J.A., 22:219
McLaughlin, J.C., 21:65 Stille, W., 22:171
Ramsey, M.A., 21:27
Mehaffey, P.C., 23:10 Stobberingh, E.E., 22:267
Rawlings, R.D., 22:235
Meijer, C.J.L.M., 23:161 Stockenhuber, C., 21:121
Reagan, D.R., 21:191
Meisler, D.M., 21:187 Stratton, C.W., 22:35
Reed, W.E., Jr., 22:209
Messer, S.A., 21:9, 23:99 Styrud, J., 22:163
Reisner, B.S., 22:325
Midolo, P.D., 21:135 Sugano, K., 23:129
Rhodes, C., 21:61
Miller, D., 21:187 Sugar, A.M., 21:129
Rimola, A., 22:141
Miller, G.H., 22:331 Suh, B., 21:111
Rinaldi, M.G., 23:99
Miller, L.A., 21:223 Sutton, L.D., 21:1, 21:181, 22:353
Rittenhouse, S.F., 21:223
Miyawaki, H., 23:77
Roark, M.K., 22:209
Morris, A.J., 21:195 Takahara, J. 23:77
Robinson, A., 21:47
Mortensen, J.E., 22:301 Takigawa, K., 23:77
Robinson, A.J., 21:77
Mosely, G.H., 21:223 Tapsall, J.W., 22:261
Romanha, A.J., 22:343
Mota Miranda, A., 22:125 Tenover, F., 21:175
Romanyk, J., 21:115
Murray, B.E., 21:119 Thomson Martin, W., 21:101
Rones, R.N., 21:141
Thomson, R.B., Jr., 23:45
Rosenblatt, J.E., 22:275, 22:279
Nakazawa, T., 23:77 Rosner, H., 22:293 Thorsen, S., 21:219
Tiballi, R.N., 23:135
Navasa, M., 22:141 Rotschafer, J.C., 22:77
Negayama, K., 23:77 Tin, L.Y., 22:135
Roussel, T.J., 21:187
Tokue, Y., 23:129
Neto, E.D., 22:343 Runehagen, A., 22:163
Nicolau, D.P., 22:49, 22:189 Runyon, B.A., 21:105 Tomayko, J.F., Jr., 21:119
Trenholme, G.M., 22:349
Nightingale, C.H., 21:47, 22:49, 22:189
Truant, A.L., 21:111
Nims, L.J., 21:65
Sader, H.S., 21:85, 21:105, 22:315
Tsai, W.-S., 22:285
Nindl, L., 23:161
Saito, D., 23:129 Tseng, C.-Y., 22:285
Ni Riain, U., 22:357
Salazar, S.A., 23:141
Tucker, L.J., 23:1
Niubo, J., 21:21
Salva, J., 21:21
Turnidge, J., 21:135, 22:57
Nix, D.E., 22:71
Salyer, J.L., 21:15
Noda, T., 23:129
Sarker, S.A., 22:337 Walboomers, J.M.M., 23:161
Norrish, B., 21:69
Satishchandran, V., 21:111 Waring, A.L., 23:89
Novak, C.C., 23:1
Scalise, G., 23:99 Washington, J.A., 21:187
Schein, M., 22:183 Weinstein, M.P., 21:55, 21:195
Odio, C.M., 22:111 Schentag, J.J., 22:71 Welch, K., 22:297
Ohkura, H., 23:129 Schmidt, B.L., 21:121 Wellhoner, M.F., 21:65
Oliveira, M.A.A., 22:343 Schneider, A., 23:161 Wenzel, R.P., 21:191
Ostergaard, B.E., 22:77
Schouten, H.C., 22:267 Weymouth, L.A., 21:61
Ostroff, R.M., 22:253 Schwartz, M., 21:169 Wiedemann, B., 22:5
Otido, J., 23:89 Scott, D.R., 23:17 Wilke, W.W., 21:181
Ouchi, K., 23:77 Sekiya, T., 23:129
Williams, K.E., 21:101
Sewell, D.L., 21:175 Wilson, M.L., 21:195
Parsons, L.M., 23:89 Shah, P.M., 22:171 Wilson, W.R., 22:129
Patel, K.B., 22:49, 22:189 Shapiro, T., 21:111
Wittmann, D.H., 21:183, 22:173
Pereda, J.M., 22:339 Shawar, R.M., 21:15 Woods, G.L., 22:325
Pérez. J.L., 21:21 Shayegani, M., 23:89
Wright, L.J., 21:203
Pestotnik, S.L., 22:167 Shi, Z.-Y., 22:285
Peterson, L.R., 23:1 Shimosato, Y., 23:129 Yamagishi, Y., 23:77
Pfaller, M.A., 21:9, 21:191, 23:99 Shur, A.L., 21:169 Yamaji, Y., 23:77
Phelps, C.L., 22:309 Shyr, J.-M., 22:285 Yaschuk, Y., 22:361
Pitre, M., 22:135 Simmons, B.P., 22:155 Yen, Y., 21:1
Pitsakis, P.G., 21:169 Simpson, A.J.G., 22:343
Young, L.S., 22:147
Platt, M.W., 21:65 Skov, R.L., 21:219 Young, R.A., 22:97
. Poupard, J.A., 21:223 Slavoski, L., 21:169
Pratt-Rippin, K., 21:187 Sloan, L.M., 22:275 Zahm, D.-M., 23:161
Prosser, B.LaT., 21:33 Smith, A.L., 22:331 Zarins, L.T., 21:27, 23:135
DIAGN MICROBIOL INFECT DIS
1996;23:167-177
Subject Index to Volumes 21-23
Abcess fluid, Coccidioides immitis in, 21:15- Escherichia coli growth on,261-—266 Area under the inhibitory serum concentra-
19 for GI carriage of vancomycin-resistant tion time-curve (AUIC), cefotaxime,
Abdominal lymphadenopathy, in Whip- enterococci, 23:119-122 22:71-76
ple’s disease, 23:111-113 for group B Streptococcus, 22:253-259 Arteflene (Ro 42-1611), against Neisseria gon-
Accuprobe MAC test, for differentiation of for intestinal strongyloidiasis, 23:141-145 orrhoeae, 23:11-13
Mycobacterium xenopi, 21:195-202 Agar dilution method Arthralgias, migratory, in Lyme borreliosis,
Acidimetric test for Acinetobacter baumannii, 23:105—110 21:121-128
nitrocefin in, 21:353-355 Etest and, 22:279-284 Arylsulfatase, in Mycobacterium xenopi eval-
S1 in, 21:353-355 for Helicobacter pylori, 21:135-140 uation, 21:195-202
Acinetobacter baumannii AIDS. See Acquired immunodeficiency syn- AUIC. see Area under the inhibitory serum
amikacin against, 23:105—110 drome concentration time-curve
aztreonam against, 23:105—110 Alamar blue reagent, in assessing Saccharo- Azithromycin
B-lactamase inhibitors against, 21:111—-114 myces cerevisiae, 23:135-140 against Bacteroides fragilis, 23:147-154
B-lactams against, 285-291 Alcaligenes xylosoxidans, cefotaxime against, against enterococci, 23:147-154
cefepime against, 22:285-291 22:43-48 against Neisseria gonorrhoeae, 23:11-13
cefoperazone against, 23:105—110 AM-1091. See Clinafloxacin against peptostreptococci, 23:147-154
cefotaxime against, 22:285-291, 23:105- AM-833. See Fleroxacin against staphylococci, 23:147-154
110 Amebiasis, Entamoeba histolytica in, 22:275- against Staphylococcus aureus, 23:147-154
ceftazidime against, 22:285-291, 23:105- 278 against Streptococcus pneumoniae, 23:147-
110 AMEs. See Aminoglycoside-modifying en- 154
ceftriaxone against, 22:285-291, 23:105—10 zymes against Streptococcus pyogenes, 23:147-154
ciprofloxacin against, 22:285-291, 23:105- Amikacin Aztreonam
110 against Acinetobacter baumannii, 23:105- against Acinetobacter baumannii, 23:105-
gentamicin against, 23:105-110 110 110
imipenem against, 22:285-291, 23:105-110 against Acinetobacter spp., 21:111-114 interpretive errors using automated sys-
meropenem against, 22:285-291 against Pseudomonas aeruginosa, 22:331- tem for susceptibility testing of, 21:
minocycline against, 23:105-110 336 57-69
norfloxacin against, 23:105—110 Aminoglycoside—modifying enzymes serious interpretive error among three
ofloxacin against, 23:105-110 (AMEs), absence of in amikacin- commercial systems for susceptibility
piperacillin against, 22:285-291, 23:105- resistant Pseudomonas aeruginosa iso- testing of, 22:249-251
110 lates, 22:331-336
ticarcillin against, 23:105—110 Aminoglycosides Bacillus cereus, cefotaxime against, 22:43-48
tobramycin against, 23:105-110 against Enterococcus faecalis, 21:85—93 BacT/ Alert, Coccidioides immitis in, 21:15-19
Acinetobacter haemolyticus, B-lactamase in- against Enterococcus faecium, 21:85—93 Bactec NR660, Coccidioides immitis in, 21:15-
hibitors against, 21:111-114 against neonatal sepsis and meningitis, 19
Acinetobacter spp. 22:111-117 Bactec 6A and 16A aerobic resin-containing
amikacin against, 21:111-114 against nosocomial pneumonia, 22:159- media, for recovery of microorgan-
B-lactams against, 21:111-114 161 isms causing peritonitis, 22:361-368
cefotaxime against, 21:111—114, 22:71-76 Amphotericin B Bactec TB method, radiometric, for Myco-
ceftazidime against, 21:111-114 against Candida parapsilopsis, 21:9-14 bacterium tuberculosis, 22:325-329
ceftriaxone against, 21:111-114 against Cryptococcus neoformans, 23:99-103 Bacteroides fragilis group
ciprofloxacin against, 21:33-45 against Saccharomyces cerevisiae, 23:135- cefotaxime against, 22:71-76
clavulanate against, 21:111-114 140 erythromycin against, 23:147—154
fleroxacin against, 21:33-45 Ampicillin Etest and, 22:279-284
imipenem against, 21:111-114 against Enterococcus faecalis, 21:85-93 roxithromycin against, 23:147-154
lomefloxacin against, 21:33-45 against Enterococcus faecium, 21:85-93 S1 in detection of, 21:1-8
ofloxacin against, 21:33-45 against neonatal sepsis and meningitis, Baermann technique, for diagnosis of intes-
piperacillin against, 21:111-114 22:111-117 tinal strongyloidiasis, 23:141-145
sulbactam against, 21:111-114 against staphylococci, 21:153-168 B-lactamase
tazobactam against, 21:111-114 Ampicillin-sulbactam Enterococcus faecalis and, 21:119
Acquired immunodeficiency syndrome against Gram-positive bacteria, 21:141- Haemophilus influenze and, 21:223-225
(AIDS) 151 S1 chromogenic cephalosporin for detec-
Cryptococcus neoformans in, 23:99-103 against Haemophilus influenzae, 21:141-151 tion of, 21:1-8, 21:353-355
disseminated toxoplasmosis in, 22:339- against staphylococci, 21:153-168 §-lactamase inhibitors
341 Animal infection models, for cephalospor- against Acinetobacter spp., 21:111-114
Acrodermatitis chronica atrophicans, in ins, 22:89-96 comparative antimicrobial activity of, 21:
Lyme borreliosis, 21:121—128 AP-PCR. See Arbitrarily primed polymer- 153-168
Actinobacillus actinomycetemcomitans, cefo- ase chain reaction effect of on oxacillin against methicillin-
taxime against, 22:43—-48 API 205, for enterococci, 21:85-93, 22:315- resistant Staphylococcus aureus, 21:81-
Aerocarditis urinae, fatal endocarditis due to, 319 84
21:219-221 Arbitrarily primed polymerase chain reac- national survey of in vitro spectrum of,
Africa, chancroid in, 23:89-98 tion (AP-PCR), for Pseudomonas cepa- 21:141-151
Agar culture cia, 23:77-83 B-lactams
Subject Index to Volumes 21-23
against Acinetobacter baumannii, 22:285- against itraconazole, 21:9-14 in dialysis patients, 22:85-87
291 strain variation in, 21:9-14 in healthy volunteers and patients, 22:
against Acinetobacter spp., 21:111-114 Capnocytophaga spp., cefotaxime against, 22: 49-55
against Enterobacter spp., 22:285-291 43-48 in moderately severe infections, 22:49-—
against Pseudomonas aeruginosa, 22:285- Carryover contamination, in PCR tech- 55
291 nique, 21:181-185 twice-daily dosage, 22:71-76
against Stenotrophomonas maltophilia, 22: Cataract extraction, extracapsular, Propioni- against Plesiomonas shigelloides, 22:43-48
285-291 bacterium acnes in, 21:187-190 against pneumococci, 22:19-33, 22:173-
Bile esculin azide, for detecting GI carriage Catheter-related blood stream infections, 182
of vancomycin-resistant enterococci, Candida parapsilopsis in, 21:9-14 against postoperative pneumonia, 22:203-
23:119-122 Cefazolin, against Propionibacterium acnes, 207
Biofilms, Candida parapsilopsis in, 21:9-14 21:187-190 against Proteus mirabilis, 22:173-182
Biosoft 1C3, CMV antigenemia-positive Cefepime against Providencia spp., 22:173-182
samples in, 21:21-25 against Acinetobacter baumannii, 22:285- against Pseudomonas aeruginosa, 22:19-33,
Blind subculture, Coccidioides immitis in, 21: 291 22:71-76, 22:285-291
15-19 against Enterobacter spp., 22:285-291 against Serratia marcescens, 22:71—76
Blood agar, subculturing for group B Strep- against Pseudomonas aeruginosa, 22:285- against severe intra-abdominal infection,
tococcus, 21:65-68 291 22:183-188
Blood culture against staphylococci, 21:153-168 against spontaneous bacterial peritonitis,
Acinetobacter baumannii in, 23:105—110 against Stenotrophomonas maltophilia, 22: 21:105-110
Aerocarditis urinae in, 21:219-221 285-291 against spontaneous bacterial peritonitis
Candida albicans in, 21:191-194 Cefoperazone, against Acinetobacter bauman- with cirrhosis, 22:141—145
Candida parapsilopsis in, 21:9-14 nii, 23:105-110 against staphylococci, 22:19-33, 22:173-
Coccidioides immitis in, 21:15-19 Cefotaxime 182
cytomegalovirus in, 21:21-25 against Acinetobacter baumannii, 22:285- against Staphylococcus aureus, 22:71-76, 22:
enterococci in, 21:85-93 291, 23:105-110 147-154, 22:173-182, 22:195-201
Neisseria meningitidis in, 21:115-117 against Acinetobacter spp., 21:111-114, 22: against Staphylococcus epidermidis, 22:195-
Rahnella aquatilis in, 22:293-296 71-76 201
Saccharomyces cerevisiae in, 23:135—140 against Actinobacillus actinomycetemcomi- against Staphylococcus saprophyticus, 22:
for sepsis detection, 23:1-9 tans, 22:43-48 195-201
viridans streptococci in, 22:267-273 against Alcaligenes xylosoxidans, 22:43—48 against Stenotrophomonas maltophilia, 22:
Bone infections, cefotaxime for, 22:105-110 against Bacteroides fragilis group, 22:71-76 285-291
Borrelia burgdorferi, PCR detection of DNA against Capnocytophaga spp., 22:43-48 against Streptococcus pneumoniae, 22:35—42
in urine and breast milk of patients against Clostridium perfringens, 22:173-182 against Streptococcus spp., 22:19-33
with Lyme borelliosis, 21:121-128 cost effectiveness in pediatrics, 22:231-233 against streptococci
Brain heart infusion agar, Escherichia coli desacetylcefotaxime and, 22:19-33, 22:49- hemolytic, 22:147—154
growth on, 261-266 55, 22:57-69, 22:77-83 pyogenic, 22:173-182
Breast milk, Borrelia burgdorferi PCR in, 21: econotherapeutics and, 22:209-217 viridans group, 22:173-182
121-128 against Eikenella corrodens, 22:43-48 against surgical infection, 22:173-182
Bronchoalveolar lavage fluid, in dissemi- against Enterobacter cloacae, 22:71-76 summation, 22:243-247
nated toxoplasmosis diagnosis in against Enterobacteriaceae, 22:57-69 therapeutic exchange of for ceftriaxone,
AIDS patients, 22:339-341 against Enterobacter spp., 22:285-291 22:235-237
Bronchoscopic study, polymicrobial bacte- against Enterococcus spp., 22:71-76 therapeutic options for, 22:77-83
rial pericarditis and, 23:115-118 against Erysipelothrix rhusiopathiae, 22:43- twice daily, 22:159-161, 22:163-166, 22:
Broth macrodilution testing 48 167-169, 22:203-207
antifungal susceptibility testing with, 21: against Escherichia coli, 22:173-182 unchanged antibacterial activity over
129-133 against Fusobacterium nucleatum, 22:43-48 years, 22:5-12
of Cryptococcus neoformans, 23:99-103 against Gram-negative pneumonia, 22: Cefotaxime (CTX)
of Haemophilus influenzae, 21:175-179 13-17 desacetylcefotaxime and, 22:97-104
in microtiter assay, 21:129-133 against Haemophilus influenzae, 22:105-110 dosing schedules for in selected institu-
of Saccharomyces cerevisiae, 23:135-140 against Haemophilus spp., 22:147-154, 22: tions, 22:147—154
standard, 21:129-133 173-182 economics of BID, 22:135-140
Broth microdilution testing against Klebsiella spp., 22:173-182 against Gram-negative bacilli, 22:125—127
of B-lactamase inhibitors against Acineto- against Neisseria spp., 22:57-69 against Haemophilus influenzae, 22:125-127
bacter spp., 21:111-114 against neonatal sepsis and meningitis, against Neisseria meningitidis, 22:125—127
of enterococci, 21:85-93, 21:95-100 22:111-117 against Staphylococcus spp., 22:125-127
RP 59500 and, 21:169-173 in the 1990's, 22:1-3 against Streptococcus pneumoniae, 22:119-
Brucella blood agar, Etest and, 22:279-284 non-ICU pathogens and, 22:13-17 123, 22:125-127
BssHII, in assessing Candida parapsilopsis against nosocomial pneumonia, 22:159- Cefotaxime-—desacetylcefotaxime (DES-
strain variation, 21:9-14 161, 22:171-172 CTX), against spontaneous bacterial
ofloxacin and, 22:71-76 peritonitis, 21:105-110
Canadian tertiary care institution, twice- once daily vs. ceftriaxone twice daily, 22: Cefpirome, against spontaneous bacterial
daily dosing of cefotaxime in, 22:135- 155-157 peritonitis, 21:105-110
140 against Pasteurella multocida, 22:43-48 Ceftazidime
Candida parapsilopsis against pediatric infections, 22:105-110 against Acinetobacter baumannii, 22:285-
against amphotericin B, 21:9-14 against pediatric meningitis, 22:125-127 291, 23:105-110
against fluconazole, 21:9-14 against Peptostreptococcus spp., 22:173-182 against Acinetobacter spp., 21:111-114
against 5-fluorocytosine, 21:9-14 pharmacokinetics of against Citrobacter freundii, 21:141-151
Subject Index to Volumes 21-23
against Enterobacteriaceae, 21:141-151 Chronic wastage, in Whipple’s disease, 23: Clonab C10/C11, CMV antigenemia-posi-
against Enterobacter spp. 21:141-151, 22: 111-113 tive samples in, 21:21-25
285-291 CI-960. See Clinafloxacin Clostridium perfringens, cefotaxime against,
against Pseudomonas aeruginosa, 22:285- Ciprofloxacin 22:173-182
291 against Acinetobacter baumannii, 22:285- Clostridium spp., Etest and, 22:279-284
against Stenotrophomonas maltophilia, 22: 291, 23:105-110 CMV. See Cytomegalovirus
285-291 against Acinetobacter spp., 21:33-45 Coagulase positivity, exfoliative toxin
Ceftizoxime, against Streptococcus pneumo- in disk diffusion testing, 21:209-213, 21: A-producing Staphylococcus aureus
niae, 22:35—42 227-230 and, 21:69-75
Ceftriaxone DU-6859a and, 21:51-54 Coccidioides immitis, in BacT/ Alert, 21:15-19
against Acinetobacter baumannii, 22:285- against Enterobacter spp., 22:285-291 Colony forming units (CFUs), group A
291, 23:105-110 against enterococci, 23:123—127 Streptococcus, 21:61—64
against Acinetobacter spp., 21:111-114 against Enterococcus faecalis, 21:27-31, 21: Colony morphology, in Mycobacterium xe-
cost effectiveness in pediatrics, 22:231-233 85-93 nopi evaluation, 21:195-202
econotherapeutics and, 22:209-217 against Enterococcus faecium, 21:85-93 Colorimetric disk assays
against Enterobacter spp., 22:285-291 against Providencia spp., 21:33-45 nitrocefin in, 21:353-355
Etest and, 22:279-284 against Pseudomonas aeruginosa, 22:285- $1 in, 21:353-355
against nosocomial pneumonia, 22:171- 291 for Saccharomyces cerevisiae, 23:135-140
172 against Pseudomonas spp., 21:33-45 Community-acquired pneumonia, switch
against Pseudomonas aeruginosa, 22:285- against Rahnella aquatilis, 22:293-296 therapy in, 22:219-223
291 against spontaneous bacterial peritonitis, Contamination, in PCR technique, 21:181-
against Stenotrophomonas maltophilia, 22: 21:105-110 185
285-291 against Staphylococcus aureus, 21:27-31, 21: Conventional culture, for group A Strepto-
against Streptococcus pneumoniae, 22:35—42 33-45 coccus, 21:61-64
therapeutic exchange of cefoxatime for, against Staphylococcus epidermidis, 21:33- Corynebacteria, and one day vs. two day
22:235-237 45 incubation of urine cultures, 21:55-56
twice daily vs. cefotaxime once daily, 22: against Staphylococcus saprophyticus, 21: Cryptococcus neoformans
155-157 33-45, 21:227-230 amphotericin B against, 23:99-103
Cell culture, of bronchoalveolar lavage fluid against Stenotrophomonas maltophilia, 22: D0870 against, 23:99-103
for diagnosis of toxoplasmosis in 285-291 DNA typing of, 23:99-103
AIDS, 22:339-341 against Xanthomonas spp., 21:33-45 fluconazole against, 23:99-103
Cell ghosts, amikacin-resistant Pseudomonas Cirrhosis, with spontaneous bacterial peri- flucytosine against, 23:99-103
aeruginosa isolates and, 22:331-336 tonitis, 22:141-145 itraconazole against, 23:99-103
Cephalosporins Citrobacter freundii triazoles against, 23:99-103
against Enterobacteriaceae, 21:153-168, 22: ceftazidime against, 21:141-151 CSF. See Cerebrospinal fluid
89-96, 22:129-134 CTX. See Cefotaxime
piperacillin-tazobactam against, 21:141-
formulary selections of, 22:129-134 151 Cutaneous infections, Enterococcus spp. in,
against Haemophilus influenzae, 22:129-134 21:141-151
Clarithromycin
interrelationship between pharmacoki- Cysteine, Escherichia coli requirement for, 22:
against Bacteroides fragilis, 23:147-—154
netics and pharmacodynamics in de- 261-266
against enterococci, 23:147—154
termining dosage regimens for Cystic fibrosis, Pseudomonas aeruginosa in,
against peptostreptococci, 23:147—154
broad-spectrum, 22:89-96 22:331-336
against staphylococci, 23:147—154
metronidazole with, for intra-abdominal Cytomegalovirus (CMV)
against Staphylococcus aureus, 23:147-154
infections, 22:189-194 antigenemia assay, monoclonal antibod-
against Streptococcus pneumoniae, 23:147-
against neonatal sepsis and meningitis, ies for, 21:21-25
154
22:111-117 specimen-dependent variability in cul-
against Streptococcus pyogenes, 23:147-154
against pneumococci, 22:105—110 ture, 21:203-207
Clavulanate, against Acinetobacter spp., 21:
against spontaneous bacterial peritonitis,
111-114
21:105-110 D0870, against Cryptococcus neoformans, 23:
Clavulanic acid, against Staphylococcus au-
against staphylococci, 22:89-96 99-103
reus, 21:81-84
against Staphylococcus aureus, 22:89-96 Dalfopristin. See RP 59500
against streptococci, 22:89-96 CLED agar, Escherichia coli growth on,261- dCTX. See Desacetylcefotaxime
Cerebrospinal fluid (CSF) 266 Dermatologic disorders, in Lyme borrelio-
Neisseria meningitidis in, 21:115-117 CLIA 88, impact of on clinical microbiolog- sis, 21:121-128
Streptococcus pneumoniae in, 22:119-123, ical laboratory, 23:35—43 Desacetylcefotaxime (dCTX)
22:35-42 Clinafloxacin (CI-960, AM-1091, PD127371) cefotaxime and, 22:19-33, 22:49-55, 22:57-
CFUs. See Colony forming units DU-6859a and, 21:51-54 69, 22:77-83, 22:97-104,
Chancroid, Haemophilus ducreyi in, 23:89-98 against Enterococcus faecalis, 21:27-31, 21: against pneumococci, 22:19-33
Children 85-93 against Pseudomonas aeruginosa, 22:19-33
cefoxatime for meningitis in, 22:125-127 against Enterococcus faecium, 21:85—93 against staphylococci, 22:19-33
Moraxella septicemia in, 21:215-217 modified criteria for disk diffusion tests, against Streptococcus pneumoniae, 22:119-
septicemia due to Vibrio cholerae 0139 Ben- 21:209-213 123
gal in, 22:337-338 against Staphylococcus aureus, 21:27-31 against Streptococcus spp., 22:19-33
Chloramphenicol Clindamycin DES-CTX. See Cefotaxime-—desacetylcefo-
against Enterococcus faecalis, 21:85-93 Etest and, 22:279-284 taxime
against Enterococcus faecium, 21:85-93 against Neisseria gonorrhoeae, 23:11-13 Dexamethasone, for neonatal sepsis and
Chloroquine, against Neisseria gonorrhoeae, Clinical microbiology laboratory director, meningitis, 22:111-117
23:11-13 changing role of, 23:45-51 DFA. See Direct fluorescent antibody
Subject Index to Volumes 21-23
Dialysis patients ELISA. See Enzyme-linked immunosorbent levofloxacin against, 22:349-352
cefotaxime in, 22:85-87 assay SCH 27899 against, 23:157—160
peritonitis in, 22:361—368 Endocarditis, fatal, Aerocarditis urinae in, 21: vancomycin-susceptible, levofloxacin
Diarrhea 219-221 against, 22:349-352
childhood, with Moraxella septicemia, 21: Endophthalmitis, chronic, Propionibacterium Enterococcus faecalis
215-217 acnes in, 21:187-—190 aminoglycosides against, 21:85-93
neonatal, Vibrio cholerae 0139 Bengal as Endotracheal intubation, pericarditis after, ampicillin against, 21:85-93
cause of, 23:155-156 23:115-118 API 20S for species idendification, 22:315-
Difco automated ESP system, for sepsis de- Entamoeba histolytica, ELISA for, 22:275-278 319
tection, 23:1-9 Enterobacter cloacae B-lactamase tests for screening, 21:119
Difco Thiol broth bottle, for sepsis detection, cefotaxime against, 22:71-76 chloramphenicol against, 21:85-93
23:1-9 pulsed-field gel electrophoresis and, 22: ciprofloxacin against, 21:27-31, 21:85-93
Direct fluorescent antibody (DFA) stain, for 309-314 clinafloxacin against, 21:27-31, 21:85-93
Giardia lamblia, 21:77-79 in spontaneous bacterial peritonitis, 21: doxycycline against, 21:85-93
Direct latex agglutination method, for 105-110 erythromycin against, 21:85-93
group B Streptococcus, 21:65-68 Enterobacteriaceae fluoroquinolones against, 21:85-93
Dirithromycin cefotaxime against, 22:57-69 gentamicin against, 21:85-93
against Bacteroides fragilis, 23:147-154 ceftazidime against, 21:141-151 glycopeptides against, 21:85-93
against enterococci, 23:147—154 cephalosporins against, 21:153-168, 22: kanamycin against, 21:85-93
against peptostreptococci, 23:147—154 89-96, 22:129-134 novobiocin against, 21:85—93
against staphylococci, 23:147—154 imipenem against, 21:153-168 penicillin against, 21:85-93
against Staphylococcus aureus, 23:147—154 piperacillin-tazobactam against, 21:141- pulsed-field gel electrophoresis and, 22:
against Streptococcus pneumoniae, 23:147- 151, 21:153-168 309-314
154 S1 in detection of, 21:1-8 RP 59500 against, 21:169-173
against Streptococcus pyogenes, 23:147-154 Enterobacterial repetitive intergenic consen- sparfloxacin against, 21:85-93
Disk diffusion susceptibility testing sus sequence PCR, of exfoliative spectinomycin against, 21:85—93
ciprofloxacin in, 21:209-213, 21:227-230 toxin A-producing Staphylococcus au- streptomycin against, 21:85-93
clinafloxacin in, 21:209-213 reus, 21:69-75 teicoplanin against, 21:85-93
DU-6859a in, 23:123-127 Enterobacter spp. tetracyclines against, 21:85-93
DV-775la in, 23:123-127 B-lactams against, 22:285-291 trimethoprim/sulfamethoxazole against,
of enterococci, 21:85—93, 21:95-100 cefepime against, 22:285-291 21:85-93
fleroxacin in, 21:209-213 cefotaxime against, 22:285-291 trospectomycin against, 21:85—93
of fluoroquinolone-resistant isolates, 21: ceftazidime against, 21:141-151, 22:285- vancomycin against, 21:85—93, 21:169-173
227-230 291 Vitek System for species idendification,
fluoroquinolones in, 21:209-213 ceftriaxone against, 22:285-291 22:315-319
of Haemophilus influenzae, 21:175-179 ciprofloxacin against, 22:285-291 Enterococcus faecium
of Helicobacter pylori, 21:135-140 imipenem against, 22:285-291 aminoglycosides against, 21:85-93
lomefloxacin in, 21:227-—230 meropenem against, 22:285-291 ampicillin against, 21:85-93
nitrocefin in, 21:1-8 piperacillin against, 22:285-291 API 20S for species idendification, 22:315-
norfloxacin in, 21:227—230 piperacillin-tazobactam against, 21:141- 319
S1 in, 21:1-8 151 chloramphenicol against, 21:85-—93
SCH 27899 in, 23:157-160 Enterococci ciprofloxacin against, 21:85-93
DNA fingerprinting, of Pseudomonas cepacia, azithromycin against, 23:147—154 clinafloxacin against, 21:85-93
23:77-83 cefotaxime against, 22:19-33 doxycycline against, 21:85-93
DNA typing clarithromycin against, 23:147-154 erythromycin against, 21:85-93
of Candida parapsilopsis, 21:9-14 desacetylcefotaxime against, 22:19-33 fluoroquinolones against, 21:85-93
dirithromycin against, 23:147-154 gentamicin against, 21:85-93
of Cryptococcus neoformans, 23:99-103
emerging multiply-resistant, 21:85-93, 21: glycopeptides against, 21:85-93
Doxycycline
95-100 kanamycin against, 21:85-93
against Enterococcus faecalis, 21:85-93
erythromycin against, 23:147—154 novobiocin against, 21:85-93
against Enterococcus faecium, 21:85-93
fluoroquinolone-resistant, 21:27-31 penicillin against, 21:85-93
against Neisseria gonorrhoeae, 23:11-13
gentamicin-resistant, 21:27-31 sparfloxacin against, 21:85—93
DU-6859a
glycopeptide-resistant spectinomycin against, 21:85-93
cross-resistance analysis for, 21:51-54
DU-6859a against, 23:123-127 streptomycin against, 21:85-93
against glycopeptide-resistant entero-
DV-775la against, 23:123—127 teicoplanin against, 21:85-93
cocci, 23:123-127
novobiocin against, 21:47—50 tetracyclines against, 21:85-93
DV-775la, against glycopeptide-resistant
ramoplanin against, 21:47—50 trimethoprim/sulfamethoxazole against,
enterococci, 23:123-127
RP 59500 against, 21:47—50 21:85-93
streptogramin against, 21:47—50 trospectomycin against, 21:85-93
Econotherapeutics, 22:209-217 vancomycin against, 21:47—50 vancomycin against, 21:85-93
EIA. See Enzyme immunoassay glycopeptides against, 21:95—100 Vitek System for species idendification,
87/312. See Nitrocefin roxithromycin against, 23:147—154 22:315-319
Eikenella corrodens, cefotaxime against, 22: teicoplanin against, 21:95—100 Enterococcus raffinosus
43-48 vancomycin against, 21:95-100 API 20S for species idendification, 22:315-
EK. See Electrophoretic karyotyping vancomycin-resistant 319
Electrophoretic karyotyping (EK) DU-6859a against, 23:123-127 Vitek System for species idendification,
of Candida parapsilopsis, 21:9-14 DV-775la against, 23:123-127 22:315-319
of Cryptococcus neoformans, 23:99-103 gastrointestinal carriage of, 23:119-122 Enterococcus spp.
Subject Index to Volumes 21-23
API 20S for species idendification, 22:315- for penicillin susceptibility testing of Fusobacterium nucleatum, cefotaxime against,
319 Neisseria meningitidis, 21:115-117 22:43-48
cefotaxime against, 22:71-76 Europe, cefotaxime dosage in, 22:147—154
nitrocefin and, 21:353-355 Everninomicins, disk diffusion testing of, Gastrointestinal (GI) tract
piperacillin-tazobactam against, 21:141- 23:157—160 group B Streptococcus in, 21:65-68
151 Exfoliative toxin A, Staphylococcus aureus, Shigella boydii in, 22:337-338
S1 and, 21:353-355 21:69-75 vancomycin-resistant enterococci in, 23:
Vitek System for species idendification, Extracorporeal membrane oxygenation, Sac- 119-122
22:315-319 charomyces cerevisiae and, 23:135-140 Genital ulcer disease, Haemophilus ducreyi in,
Enzyme immunoassay (EIA) Extraintestinal infection, Vibrio cholerae 0139 23:89-98
for group B Streptococcus, 22:321-324 Bengal in, 22:337-338 Genomic tests, of exfoliative toxin A-pro-
for Mycoplasma pneumoniae, 23:85-88 ducing Staphylococcus aureus, 21:69-
Enzyme-linked immunosorbent assay Fansidar. See Sulfadoxine—pyrimethamine 75
(ELISA) Fecal specimens, Giardia lamblia in, 21:77-79 Genotypic diversity, of Candida parapsilopsis,
for Entamoeba histolytica, 22:275-278 Feminine hygiene products, effect of on 21:9-14
for Giardia lamblia, 21:77-79 group B Streptococcus detection, 22: Gen-Probe direct test, for Mycobacterium tu-
for Mycoplasma pneumoniae, 23:85-88 253-259 berculosis, 22:297-299
Enzyme-producing species, $1 in detection Flavobacterium spp., cefotaxime against, 22: Gentamicin
of, 21:1-8 43-48 against Acinetobacter baumannii, 23:105-
Enzymes, for Borrelia burgdorferi DNA de- Fleroxacin (Ro 23-6240, AM-833) 110
tection, 21:121-128 against Acinetobacter spp., 21:33-45 enterococcal resistance to, 21:27-31
Eosinophilia, in strongyloidiasis, 23:141-145 DU-6859a and, 21:51-54 against Enterococcus faecalis, 21:85-93
Error-rate bounding methods modified criteria for disk diffusion tests, against Enterococcus faecium, 21:85—93
ciprofloxacin and, 21:227-230 21:209-213 against staphylococci, 21:169-173
for Helicobacter pylori, 21:135-140 against Providencia spp., 21:33-45 Germany, cefotaxime dosage in, 22:147—154
lomefloxacin and, 21:227-230 against Pseudomonas spp., 21:33-45 GI tract. See Gastrointestinal tract
norfloxacin and, 21:227-230 against Staphylococcus aureus, 21:33-45 Giardia lamblia, ELISA assays for, 21:77-79
Erysipelothrix rhusiopathiae, cefotaxime against Staphylococcus epidermidis, 21:33- Glucose, Candida parapsilopsis in, 21:9-14
against, 22:43-48 45 §-p-Glucuronidase, among Escherichia coli
Erythema migrans, in Lyme borreliosis, 21:121- against Staphylococcus saprophyticus, 21: and Enterobacteriaceae causing uri-
128 33-45 nary tract infections, 22:261-266
Erythromycin against Xanthomonas spp., 21:33-45 Glycopeptides
against Bacteroides fragilis, 23:147-154 Fluconazole enterococcal resistance to, 21:47-50, 21:
against enterococci, 23:147—154 against Candida parapsilopsis, 21:9-14 95-100, 23:123-127
against Enterococcus faecalis, 21:85-93 against Cryptococcus neoformans, 23:99-103 against Enterococcus faecalis, 21:85-93
against Enterococcus faecium, 21:85-93 against Saccharomyces cerevisiae, 23:135- against Enterococcus faecium, 21:85-93
against peptostreptococci, 23:147—154 140 Gram-negative spp.
staphylococcal resistance to, 21:69-75 cefotaxime against, 22:57-69, 22:125-127,
Flucytosine
against staphylococci, 23:147—154 22:159-161
against Cryptococcus neoformans, 23:99-103
against Staphylococcus aureus, 23:147-154 fluoroquinolones against, 21:33-45
against Saccharomyces cerevisiae, 23:135-
against Streptococcus pneumoniae, 23:147- in HIV, 22:293-296
140
154 in intensive care units, 22:285-291
5-Fluorocytosine, against Candida parapsilop-
against Streptococcus pyogenes, 23:147-154 piperacillin-tazobactam against, 21:141-
against Vibrio cholerae 0139 Bengal, 23: sis, 21:9-14
151, 21:153-168
Fluoroquinolone-resistant isolates, in disk
155-156
Gram-positive spp.
diffusion susceptibility testing, 21:
Escherichia coli
Aerococcus spp. and, 21:219-221
227-230
amoxicillin against, 22:301-306
ampicillin-sulbactam against, 21:141-151
Fluoroquinolones
amoxicillin-clavanulate against, 22:301-
cefotaxime against unusual, 22:43-48
306 enterococcal resistance to, 21:27-31
fluoroquinolones against, 21:33-45
cefaclor against, 22:301-306 against Enterococcus faecalis, 21:85-93
furopenem against, 22:301-306
cefixime against, 22:301-—306 against Enterococcus faecium, 21:85-93
imipenem against, 21:141—151
cefotaxime against, 22:173-182 against glycopeptide-resistant entero-
nitrocefin and, 21:353-355
cefpodoxime against, 22:301-306 cocci, 23:123—127
piperacillin-tazobactam against, 21:141-
cefuroxime against, 22:301-306 against Haemophilus influenzae, 21:175-179
151
clarithromycin against, 22:301-306 in vitro activities of, 21:33-45
SCH 27899 against, 23:157—160
furopenem against, 22:301-306 modified criteria for disk diffusion tests,
in neonatal sepsis and meningitis, 22:111- 21:209-213 S1 and, 21:1-8, 21:353-355
117 against spontaneous bacterial peritonitis, Gram stain, of Coccidioides immitis, 21:15-19
piperacillin—tazobactam against, 21:141- 21:105-110 Grepafloxacin (OPC 17116), against Haemo-
151 Formalin-ethyl acetate concentration philus influenzae, 21:175-179
pulsed-field gel electrophoresis and, 22: method, for diagnosis of intestinal groEl gene, Haemophilus ducreyi, 23:89-98
309-314 strongyloidiasis, 23:141—145 Gynecologic infections, Enterococcus spp. in,
in spontaneous bacterial peritonitis, 21: Formazan dye, in microtiter assay, 21:129- 21:141-151
105-110 133
Etest Fungi Haemophilus influenzae
for anaerobic bacteria, 22:279-284 NCCLS standard broth macrodilution as- amoxicillin against, 22:301-306
for enterococci, 21:85-93, 21:95-100 say for, 21:129-133 amoxicillin-clavanulate against, 22:301-
for Helicobacter pylori, 21:135-140 sepsis and, 23:1-9 306
Subject Index to Volumes 21-23
ampicillin-sulbactam against, 21:141-151 tem for susceptibility testing of, 21: in spontaneous bacterial peritonitis, 21:
B-lactamase producing, 21:223-225 57-69 105-110
cefaclor against, 22:301-306 against Pseudomonas aeruginosa, 22:285- Klebsiella spp., cefotaxime against, 22:173-
cefixime against, 22:301—306 291 182
cefotaxime against, 22:105-110, 22:125- against staphylococci, 21:153-168
127 against Stenotrophomonas maltophilia, 22: Lactation, in Lyme borreliosis, 21:121-128
cefpodoxime against, 22:301-306 285-291 Larva, strongyloides, 23:141-145
cefuroxime against, 22:301—306 Immunocompromised individuals, cyto- Legionella pneumophila serogroup Lansing 3,
cephalosporins against, 22:129-134 megalovirus in, 21:203—207
pneumonia with pleural effusion due
clarithromycin against, 22:301—306 Immunofluorescent antibody assay (IFA), to, 21:101-103
fluroquinolones against, 21:175-179 for Mycoplasma pneumoniae, 23:85-88
Leptospira interrogans, differential diagnosis
furopenem against, 22:301—306 Immunosuppressive agents, Legionella pneu- of, 22:343-348
grepafloxacin against, 21:175-179 mophila serogroup Lansing 3 and, 21:
Levofloxacin
imipenem against, 21:141-151 101-103
DU-6859a and, 21:51-54
PF 131628 against, 21:175-179
Indirect hemagglutination test (IHA), for
against glycopeptide-resistant entero-
piperacillin-tazobactam against, 21:141-
Entamoeba histolytica, 22:275-278
cocci, 23:123-127
151, 21:153-168
Infants, pharmacokinetics of cefotaxime and
LIM-selective broth medium, group B,
S1 in detection of, 21:1-8
desacetylcefotaxime in, 22:97-104
Haemophilus spp., cefotaxime against, 22: Streptococcus enrichment in, 22:321-
Intensive care unit (ICU)
324
147-154, 22:173-182
cefotaxime use outside of, 22:13-17
Listeria monocytogenes
Health care reform in the 1990's, and clinical
Gram-negative bacilli resistance and, 22:
cefotaxime against, 22:43-48
microbiology laboratory, 23:15-16,
285-291
23:75-76 in neonatal sepsis and meningitis, 22:111-
Health maintenance organizations (HMOs), neonatal, Candida albicans as nosocomial 117
pathogen in, 21:191-194
clinical microbiology in, 23:17-21 Lomefloxacin
Intra-abdominal infections
Helicobacter pylori, metronidazole against, against Acinetobacter spp., 21:33-45
cefotaxime against, 22:183-188
21:135-140 in disk diffusion susceptibility testing, 21:
cephalosporin—metronidazole combina-
High-grade squamous intraepithelial le- 227-230
tions for, 22:189-194
sions, human papillomavirus detec- against Providencia spp., 21:33-45
Enterococcus spp. in, 21:141-151
tion in, 23:161-163 against Pseudomonas spp., 21:33-45
HIV. See Human immunodeficiency virus metronidazole against, 22:183-188 against Staphylococcus aureus, 21:33-45
HMOs. See Health maintenance organiza- Intrapartum carriage, of group B Streptococ- against Staphylococcus epidermidis, 21:33-
tions cus, 21:65-68 45
Hospital formularies Intravenous drug abuser, Rahnella aquatilis against Staphylococcus saprophyticus 21:33-
cephalosporin selection for, 22:129-134 bacteremia in HIV-infected, 22:293- 45, 21:227-230
MART for formulary replacement, 22: 296 against Xanthomonas spp., 21:33-45
239-242 Intravenous rehydration therapy, for Vibrio Lower respiratory tract infections, Pseudomo-
HPV. See Human papillomavirus cholerae 0139 Bengal-induced diar- nas aeruginosa in, 21:141-151
rhea, 23:155-156
Human immunodeficiency virus (HIV) Lyme borreliosis, PCR detection of Borrelia
Itraconazole
Legionella pneumophila serogroup Lansing burdorferi in, 21:121-128
3 in, 21:101-103 against Candida parapsilopsis, 21:9-14
Mycobacterium xenopi in, 21:195-202 against Cryptococcus neoformans, 23:99-103
MAC. See Mycobacterium avium complex
Rahnella aquatilis in, 22:293-296 against Saccharomyces cerevisiae, 23:135-
MacConkey agar
140
Human papillomavirus (HPV), in high-
Escherichia coli growth on, 261-266
grade squamous intraepithelial le-
without crystal violet, in Mycobacterium
sions, 23:161-—163 Joint infections, cefotaxime for, 22:105-110
xenopi evaluation, 21:195—202
Hybrid capture assay, for human papillo-
Macrobroth dilution method, for Propioni-
mavirus detection, 23:161-163 Kanamycin bacterium acnes, 21:187—190
Hypersensitivity pneumonitis, Legionella against Enterococcus faecalis, 21:85-93 Macrodilution assay, antifungal testing
pneumophila serogroup Lansing 3 in, against Enterococcus faecium, 21:85-93 with, 21:129-133
21:101-103
Kirby—Bauer disk diffusion method, modi- Macrolides
fied, for Helicobacter pylori, 21:135- against Neisseria gonorrhoeae, 23:11-13
ICU. See Intensive care unit 140 resistance to in Taiwanese bacteria, 223:
IFA. See Immunofluorescent antibody assay Klebsiella oxytoca, B-D-glucuronidase activity 147-154
IgG/IgM antibody test system, for Myco- in, 22:261-266 Macrorestriction digest profiles, of Candida
plasma pneumoniae, 23:85-88 Klebsiella pneumoniae parapsilopsis, 21:9-14
IHA. Seelndirect hemagglutination test amoxicillin against, 22:301-—306 Malaria, antigonococcal activity of drugs
Imipenem amoxicillin-clavanulate against, 22:301- used against, 23:11-13
against Acinetobacter baumannii, 22:285- 306 MART. See Multidisciplinary antibiotic re-
291, 23:105-110 cefaclor against, 22:301-306 view team
against Acinetobacter spp., 21:111-114 cefixime against, 22:301-306 MBCs. See Minimum bactericidal concentra-
against Enterobacteriaceae, 21:153-168 cefpodoxime against, 22:301-306 tions
against Enterobacter spp., 22:285-291 cefuroxime against, 22:301-306 McFarland standard, Etest and, 22:279-284
against Gram-positive bacteria, 21:141- clarithromycin against, 22:301-306 Mediastinitis, polymicrobial bacterial per-
151 furopenem against, 22:301-306 carditis with, 23:115-118
against Haemophilus influenzae, 21:141-151 pulsed-field gel electrophoresis and, 22: Mefloquine, against Neisseria gonorrhoeae,
interpretive errors using automated sys- 309-314 23:11-13
Subject Index to Volumes 21-23
Membrane enzyme-linked immunoassay, cefpirome, 21:105-110 Minocycline, against Acinetobacter bauman-
for Mycoplasma pneumoniae, 23:85-88 cefpodoxime, 22:301-306 nii, 23:105—110
Meningitis ceftazidime, 21:111—114, 22:119-123, 22: Molecular biology, encyclopedia of, 22:307
cefotaxime for, 22:105—110, 22:111—117, 22: 285-291, 23:105—110 Molecular typing, of Candida parapsilopsis,
125-127 ceftizoxime, 22:35—42 21:9-14
Streptococcus pneumoniae in, 22:35—42 ceftriaxone, 21:111-114, 22:35-42, 22:119- Monoclonal antibodies, for cytomegalovirus
Meropenem 123, 22:285-291, 23:105-110 antigenemia assay, 21:21—25
against Acinetobacter baumannii, 22:285- cefuroxime, 22:301-306 Monofluo kit CMV, CMV antigenemia-
291 cephalosporin, 21:105-110, 22:89-96 positive samples in, 21:21—25
against Enterobacter spp., 22:285-291 chloramphenicol, 22:119-123 Moraxella catarrhalis
against Pseudomonas aeruginosa, 22:285- chloroquine, 23:11-13 amoxicillin against, 22:301-306
291 ciprofloxacin, 21:27-31, 21:33-45, 21:51- amoxicillin-clavanulate against, 22:301-
against Stenotrophomonas maltophilia, 22: 54, 21:105-110, 21:227-230, 22:285- 306
285-291 291, 23:105-110, 23:123—127 cefaclor against, 22:301-306
Methicillin, staphylococcal resistance to 21: clarithromycin, 22:301-—306, 23:147-154 cefixime against, 22:301-306
27-31, 21:81-84, 22:301-306, 23:157- clavulanate, 21:111-114 cefpodoxime against, 22:301-306
160 clavulanic acid, 21:81-84 cefuroxime against, 22:301-306
Metronidazole clinafloxacin, 21:27-31, 21:51-54 clarithromycin against, 22:301-306
against anaerobic isolates, 21:153—168 clindamycin, 23:11-13 furopenem against, 22:301-306
against Helicobacter pylori, 21:135-140 desacetylcefotaxime, 22:19-33, 22:119-123 piperacillin-tazobactam against, 21:153-
against intra-abdominal infections, 22: dirithromycin, 23:147-154 168
183-188, 22:189-194 doxycycline, 23:11-13 S1 in detection of, 21:1-8
Mg?*, AP-PCR and, 23:77-83 DU-6859a, 21:51-54, 23:123-127 Moraxella spp., in septicemia in children
Mait mycobacteria growth indicator tubes, DV-775la, 23:123-127 with diarrheal disease, 21:215-217
for Mycobacterium tuberculosis, 22: erythromycin, 23:147—154 Molds, NCCLS standard broth macrodilu-
325-329 fleroxacin, 21:33-45, 21:51-54 tion assay for, 21:129-133
Microtiter-based assay, antifungal testing fluconazole, 21:9-14, 23:135-140 Multidisciplinary antibiotic review team
with, 21:129-133 flucytosine, 23:135-140 (MART), for hospital formulary re-
Middlebrook broth, in Mycobacterium xenopi 5-fluorocytosine, 21:9-14 placement, 22:239-242
evaluation, 21:195—202 fluoroquinolone, 21:105—110 Myalgias, migratory, in Lyme borreliosis,
Minimum bactericidal concentrations furopenem, 22:301-306 21:121-128
(MBCs) gentamicin, 23:105-110 Mycobacteria, non-RI SSCP in identification
amphotericin B, 21:131 imipenem, 21:111-114, 22:285-291, 23: of, 23:129-133
cefazolin, 21:187-190 105-110 Mycobacterium avium complex (MAC), dif-
fluconazole, 21:131 itraconazole, 21:9-14, 23:135-140 ferentiation of from Mycobacterium
grepafloxacin, 21:175-179 levofloxacin, 21:51-54, 23:123-127 xenopi, 21:195-202
ketoconazole, 21:131 lomefloxacin, 21:33-45, 21:227-230 Mycobacterium tuberculosis
novobiocin, 21:47—50 macrolide, 23:11-13 Gen-Probe direct test for, 22:297-299
PD 131628, 21:175-179 mefloquine, 23:11—13 growth indicator tubes for, 22:325-329
penicillin, 21:187—190 meropenem, 22:285-291 isoniazid against, 22:325-329
ramoplanin, 21:47—50 minocycline, 23:105—110 PCR for, 22:357—360
RP 59500, 21:47—-50 norfloxacin, 21:227—230, 23:105-110 rifampin against, 22:325-329
streptogramin, 21:47—50 Mycobacterium xenopi, differentiation of
novobiocin, 21:47—50
vancomycin, 21:187-—190 from Mycobacterium avium complex,
ofloxacin, 21:33-45, 21:51-54, 21:105-110,
XTT assay and, 21:129-133 21:195-202
23:105-110, 23:123-127
Minimum inhibitory concentrations (MICs) Mycoplasma pneumoniae, rapid enzyme im-
oxacillin, 21:81-84
amikacin, 21:111-114, 22:331-336, 23:105- munoassay system for serologic di-
penicillin, 21:115-117, 21:187-190
110 agnosis of, 23:85-88
piperacillin, 21:111-114, 22:285-291, 23:
amoxicillin, 22:301—306
105-110
amoxicillin—clavulanate, 22:301-—306 Nasopharyngeal carcinoma, polymicrobial
primaquine, 23:11-13
amphotericin B, 21:9-14, 23:135-140 bacterial pericarditis and, 23:115-118
pyrimethamine, 23:11-13
arteflene, 23:11-13 Neck abcess fluid, Coccidioides immitis in, 21:
quinacrine, 23:11—13
azithromycin, 23:11—13, 23:147-154 15-19
quinine, 23:11-13
aztreonam, 23:105-110 Neisseria gonorrhoeae
B-lactam, 21:111-114, 22:285-291 ramoplanin, 21:47-50 arteflene against, 23:11—13
B-lactamase inhibitor, 21:111-114 rifampin, 22:119-123 azithromycin against, 23:11-13
cefaclor, 22:301-306 roxithromycin, 23:147-154 chloroquine against, 23:11-13
RP 59500, 21:47-50
cefazolin, 21:187-190 clindamycin against, 23:11-13
cefepime, 22:285-291 sparfloxacin, 21:51—54 doxycycline against, 23:11-13
cefixime, 22:301-306 streptogramin, 21:47—-50 macrolides against, 23:11—13
cefoperazone, 23:105-110 sulbactam, 21:81-84, 21:111-114 mefloquine against, 23:11-13
cefotaxime, 21:105—110, 21:111-114, 22:13- sulfadoxine—pyrimethamine, 23:11-13 piperacillin-tazobactam against, 21:153-
17, 22:19-33, 22:35-42, 22:43-48, 22: tazobactam, 21:81-84, 21:111-114 168
57-69, 22:71-76, 22:77-83, 22:89-96, teicoplanin, 21:95-100 primaquine against, 23:11-13
23:105-110, 22:119-123, 22:173-182, ticarcillin, 23:105—110 pyrimethamine against, 23:11—13
22:195-201, 22:285-291 tobramycin, 23:105—110 quinacrine against, 23:11-13
cefotaxime—desacetylcefotaxime, 21:105- vancomycin, 21:47—50, 21:95-100, 21:187- quinine against, 23:11-13
110 190, 22:119-123 S1 in detection of, 21:1-8
Subject Index to Volumes 21-23
sulfadoxine—pyrimethamine against, 23: against glycopeptide-resistant entero- pH, AP-PCR and, 23:77-83
11-13 cocci, 23:123—127 Phage typing, of exfoliative toxin A-produc-
Neisseria meningitidis against Providencia spp., 21:33-45 ing Staphylococcus aureus, 21:69-75
cefoxatime against, 22:125-127 against Pseudomonas spp., 21:33-45 Pharmacoeconomics, antimicrobial, 22:225-
penicillin against, 21:115-117 against spontaneous bacterial peritonitis, 229
Neisseria spp., cefotaxime against, 22:57-69 21:105-110 Pharyngitis, group A Streptococcus, 21:61—-64
Neonatal intensive care unit, Candida albi- against Staphylococcus aureus, 21:33-45 Phenotypic typing, of Pseudomonas cepacia,
cans as nosocomial pathogen in, 21: against Staphylococcus epidermidis, 21:33- 23:77-83
191-194 45 Pigmentation in response to light, in Myco-
Neonates against Staphylococcus saprophyticus, 21: bacterium xenopi evaluation, 21:195-
exfoliative toxin A-producing Staphylococ- 33-45 202
cus aureus in, 21:69-75 against Xanthomonas spp., 21:33-45 Piperacillin
group B Streptococcus infections in, 21:65- OIA. See Optical immunoassay against Acinetobacter baumannii, 22:285-
68 OPC 17116. See Grepafloxacin 291, 23:105-110
meningitis in, 22:111-117 Operation Desert Storm, Whipple’s disease against Acinetobacter spp., 21:111-114
sepsis in, 22:111-117 and, 23:111-113 against Enterobacteriaceae, 21:141-151, 21:
Vibrio cholerae 0139 Bengal causes diar- Optical immunoassay (OIA) 153-168
rhea in, 23:155-156 for group A Streptococcus, 21:61-64 against Enterobacter spp., 22:285-291
Neoplasm, Whipple’s disease mimicking for group B Streptococcus, 22:253-259 against Pseudomonas aeruginosa, 22:285-
malignant, 23:111-113 Ova & Parasite concentration, for Giardia 291
New technology, evaluation of in clinical lamblia, 21:77-79 against staphylococci, 21:153-168
microbiology laboratory, 23:53-60 Oxacillin, against Staphylococcus aureus, against Stenotrophomonas maltophilia, 22:
p-Nitro-a-acetylamino-B-hydroxypro- 21:81-84 285-291
piophenone, in Mycobacterium xenopi Piperacillin-tazobactam
evaluation, 21:195-202 Packaged culture media, for sepsis detec- against Bacteroides fragilis, 21:153-168
Nitrocefin (87/312), for B-lactamase detec- tion, 23:1-9 against Citrobacter freundii, 21:141-151
tion, 21:1-8, 21:353-355 Parallel and blind study, to assess anti-pp65 against Enterobacter spp. 21:141-151
Nondenaturing silver-stained polyacryl- monoclonal antibodies for CMV an- against Enterococcus spp., 21:141-151
amide gel analysis, of PCR products tigenemia assay, 21:21-—25 against Escherichia coli, 21:141-151
for differential diagnosis of Leptospira Pasteurella multocida, cefotaxime against, against Gram-negative bacilli, 21:141—151,
interrogans, 22:343-348 22;43—-48 21:153-168
Nonradioisotopic single-strand conforma- Plesiomonas shigelloides, cefotaxime against, against Gram-positive cocci, 21:141-151
tion polymorphism analysis, myco- 22:43-48 against Haemophilus influenzae, 21:141-
bacteria identified via, 23:129-133 PCR. See Polymerase chain rection 151, 21:153-168
Norfloxacin PD 131628, against Haemophilus influenzae, against Moraxella catarrhalis, 21:153-168
against Acinetobacter baumannii, 23:105- 21:175-179 national survey of in vitro spectrum of,
110 PD127371. See Clinafloxacin 21:141-151
in disk diffusion susceptibility testing, 21: Pediatric infections, cefotaxime for, 22:105- against Neisseria gonorrhoeae, 21:153-168
227-230 110 against Pseudomonas aeruginosa, 21:141-
against Staphylococcus saprophyticus, 21: Pediatric meningitis, cefoxatime for, 22:125- 151
227-230 127 against staphylococci, 21:153-168
Nosocomial pathogen Penicillin Plasmodium spp., antigonococcal activity of
Candida albicans as, 21:191-194 against Bacteroides fragilis, 21:169-173 drugs used against, 23:11-13
Candida parapsilopsis as, 21:9-14 against Neisseria meningitidis, 21:115-117 Pleural effusion, in pneumonia, 21:101—103
Enterococcus spp. as, 21:141-151 against pneumococci, 22:105-110 Pneumococcal meningitis, Streptococcus
Pseudomonas cepacia as, 23:77-83 against Propionibacterium acnes, 21:187- pneumoniae in, 22:35—42
Nosocomial pneumonia 190 Pneumococci
streptococcal resistance to, 22:119-123 cefotaxime against, 22:19-33, 22:173-182
aminoglycosides against, 22:159-161
against Streptococcus pneumoniae, 22:35- cephalosporins against, 22:105—110
cefotaxime against, 22:159-161, 22:171-
42, 22:301-306 desacetylcefotaxime against, 22:19-33
172
Peptostreptococci penicillin against, 22:105-110
ceftriaxone against, 22:171-172
azithromycin against, 23:147-154 Pneumonia
No-target false-positives, in PCR technique,
aminoglycosides against, 22:159-161
cefotaxime against, 22:173-182
21:181-185
clarithromycin against, 23:147-154 cefotaxime against, 22:13-17, 22:159-161,
Novobiocin
dirithromycin against, 23:147-154 22:203-207
against Enterococcus faecalis, 21:85-93 erythromycin against, 23:147—154 with pleural effusion, Legionella pneumo-
against Enterococcus faecium, 21:85-93 roxithromycin against, 23:147—154 phila serogroup Lansing 3 in, 21:101-
against glycopeptide-resistant entero- Perforated bowel, Saccharomyces cerevisiae 103
cocci, 21:47—-50 in, 23:135-140 switch therapy in, 22:219-223
Pericarditis, after endotracheal intubation, Polymerase chain reaction (PCR)
Obstetric outpatients, group B Streptococcus 23:115-118 automation of, 21:181-—185
infections in, 21:65-68 Peritonitis for Borrelia burgdorferi, 21:121-128
Ofloxacin BACTEC media for microorganisms in, 22: for exfoliative toxin A-producing Staphy-
against Acinetobacter baumannii, 23:105- 361-368 lococcus aureus, 21:69-75
110 Saccharomyces cerevisiae in, 23:135-140 for Haemophilus ducreyi groEl gene, 23:89-
against Acinetobacter spp., 21:33-45 Persian Gulf veterans, Whipple’s disease 98
cefotaxime and, 22:71-76 and, 23:111-113 for human papillomavirus, 23:161-163
DU-6859a and, 21:51-54 PFGE. See Pulsed-field gel electrophoresis for Leptospira interrogans, 22:343-348